Neoantigen Targeted Therapies Global Market Report 2024

Description

Neoantigen-targeted therapies represent a precision medicine approach focused on leveraging neoantigens within cancer cells. Neoantigens, distinct antigens arising from genetic abnormalities in cancer cells, become the target for harnessing the body's immune system to specifically identify and combat cancer.

These therapies fall into two main categories, monotherapy and combination therapy. Monotherapy involves utilizing a single medicine or therapeutic approach to address the disease. Immunotherapy options encompass DNA or RNA-based vaccines, protein-based vaccines, dendritic cell vaccines, and TIL-based therapies, with applications spanning colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancer. Administration routes include intradermal, intravenous, and subcutaneous, while applications extend to medical research institutions, hospitals, clinics, and other healthcare settings.

The neoantigen targeted therapies market research report is one of a series of new reports from The Business Research Company that provides neoantigen targeted therapies market statistics, including the neoantigen targeted therapies industry global market size, regional shares, competitors with a neoantigen targeted therapies market share, detailed neoantigen targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. This neoantigen targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $2.43 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 39.3%. The growth observed during the historical period can be attributed to several factors, including advancements in genomic sequencing, the evolution of immunotherapy, increased understanding of tumor immunology, the successful implementation of checkpoint inhibitors in clinical settings, and progress in molecular profiling technologies.

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $11.69 billion in 2028 at a compound annual growth rate (CAGR) of 36.3%. The anticipated growth in the forecast period is expected to result from advancements in bioinformatics, the expansion of precision medicine, the development of neoantigen vaccines, the adoption of therapeutic combination strategies, and the validation of biomarkers. Noteworthy trends in the forecast period encompass the management of neoantigen resistance, the utilization of neoantigen-primed adoptive cell therapies, the exploration of neoantigen-based combinatorial therapies, the integration of real-world data, and the enhancement of predictive models.

The anticipated growth in the neoantigen targeted therapies market is primarily attributed to the increasing incidence of cancer cases. This refers to the rise in new cancer cases within a specific population during a given period. Neoantigen targeted therapies, often administered in combination, are instrumental in treating various types of cancer. In 2022, the American Cancer Society reported a substantial increase in new cancer cases in the United States, reaching 1.9 million. Additionally, 609,360 deaths were attributed to cancer in the same year, underscoring the profound impact of the disease. Consequently, the surge in cancer incidence is a key driver propelling the growth of the neoantigen targeted therapies market.

The growth of the market is expected to be fueled by the increasing prominence of precision oncology. Precision oncology involves tailoring cancer treatment based on detailed genetic and molecular information about a patient's tumor. Neoantigen-targeted therapies play a pivotal role in precision oncology by utilizing advanced genomic analysis to identify unique neoantigens expressed by an individual's cancer cells. This approach allows for a more personalized and effective treatment option, addressing the specific genetic makeup of each patient's tumor. The prevalence of precision oncology is evident in the increasing adoption of next-generation sequencing (NGS), with 60% of oncologists frequently using NGS in over 75% of cases, as reported by Novartis AG in its 2021 precision oncology annual trend report. This signifies a growing percentage of cancer patients benefiting from the precision oncology approach. Consequently, the rise of precision oncology is a key factor driving the growth of the neoantigen targeted therapies market.

Product innovation has become a prominent trend within the neoantigen targeted therapies market, with major players prioritizing the development of inventive products to establish leadership. A notable example is BioNTech, a Germany-based biotechnology company, which, in October 2021, expanded its clinical oncology portfolio by initiating a Phase 2 clinical trial for 'BNT122,' an mRNA-based individualized immunotherapy. This trial, focusing on colorectal cancer patients, represents a significant milestone, with the first patient dosed with BNT122. The innovative approach of stimulating a targeted T-cell response against neoantigens in each patient's tumor showcases BioNTech's commitment to advancing cutting-edge immunotherapies and broadening treatment options for cancer patients.

Key players in the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize neoantigen vaccines and monoclonal antibody drugs, addressing challenges in existing immunotherapy for solid tumors. Strategic partnerships involve leveraging complementary strengths and resources for mutual benefits. An example is the partnership between Innovent Biologics, a China-based biopharmaceutical company, and NeoCura Bio-Medical Technology Co. Ltd., a China-based precision healthcare and medical technology company. Their collaboration, initiated in October 2021, aims to evaluate the combination therapy of sintilimab and the neoantigen vaccine NEO_PLIN2101 for cancer treatment in China, assessing safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in cancer patients.

In August 2021, BioNTech SE, another Germany-based biotechnology company, acquired Kite Pharma's Neoantigen TCR cell therapy platform, further exemplifying the commitment to leveraging the immune system to combat cancer. This strategic move not only strengthens BioNTech's position in the innovative cell-based therapies field but also aligns with the company's broader goals in advancing cancer treatment. Kite Pharma, a US-based company specializing in cell therapy and immunotherapy, operates within the neoantigen targeted therapies market.

Major companies operating in the neoantigen targeted therapies market report are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics PLC, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

North America was the largest region in the neoantigen targeted therapies market in 2023. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neoantigen targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neoantigen Targeted Therapies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neoantigen targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neoantigen targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neoantigen targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Monotherapy; Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines; Protein-Based Vaccines; Dendritic Cell Vaccines; TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer; Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Bone Cancer; Gynecological Cancer
4) By Route of Administration: Intradermal; Intravenous; Subcutaneous
5) By Application: Medical Research Institution; Hospital; and Clinic; Other Applications
Companies Mentioned: F. Hoffmann-La Roche AG; Merck and Co. Inc.; Bristol Myers Squibb Company; GlaxoSmithKline plc; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13763

1. Executive Summary

2. Neoantigen Targeted Therapies Market Characteristics

3. Neoantigen Targeted Therapies Market Trends And Strategies

4. Neoantigen Targeted Therapies Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Neoantigen Targeted Therapies Market Size and Growth

5.1. Global Neoantigen Targeted Therapies Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Neoantigen Targeted Therapies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Neoantigen Targeted Therapies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neoantigen Targeted Therapies Market Segmentation

6.1. Global Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Monotherapy
Combination Therapy
6.2. Global Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
DNA Or RNA-Based Vaccines
Protein-Based Vaccines
Dendritic Cell Vaccines
TIL-Based Therapies
6.3. Global Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Colorectal Cancer
Renal Cell Carcinoma
Non-Small Cell Lung Cancer
Bone Cancer
Gynecological Cancer
6.4. Global Neoantigen Targeted Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Intradermal
Intravenous
Subcutaneous
6.5. Global Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Medical Research Institution
Hospital And Clinic
Other Applications

7. Neoantigen Targeted Therapies Market Regional And Country Analysis

7.1. Global Neoantigen Targeted Therapies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Neoantigen Targeted Therapies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neoantigen Targeted Therapies Market

8.1. Asia-Pacific Neoantigen Targeted Therapies Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neoantigen Targeted Therapies Market

9.1. China Neoantigen Targeted Therapies Market Overview
9.2. China Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neoantigen Targeted Therapies Market

10.1. India Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neoantigen Targeted Therapies Market

11.1. Japan Neoantigen Targeted Therapies Market Overview
11.2. Japan Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neoantigen Targeted Therapies Market

12.1. Australia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neoantigen Targeted Therapies Market

13.1. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neoantigen Targeted Therapies Market

14.1. South Korea Neoantigen Targeted Therapies Market Overview
14.2. South Korea Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neoantigen Targeted Therapies Market

15.1. Western Europe Neoantigen Targeted Therapies Market Overview
15.2. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neoantigen Targeted Therapies Market

16.1. UK Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neoantigen Targeted Therapies Market

17.1. Germany Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neoantigen Targeted Therapies Market

18.1. France Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neoantigen Targeted Therapies Market

19.1. Italy Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neoantigen Targeted Therapies Market

20.1. Spain Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neoantigen Targeted Therapies Market

21.1. Eastern Europe Neoantigen Targeted Therapies Market Overview
21.2. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neoantigen Targeted Therapies Market

22.1. Russia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neoantigen Targeted Therapies Market

23.1. North America Neoantigen Targeted Therapies Market Overview
23.2. North America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neoantigen Targeted Therapies Market

24.1. USA Neoantigen Targeted Therapies Market Overview
24.2. USA Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neoantigen Targeted Therapies Market

25.1. Canada Neoantigen Targeted Therapies Market Overview
25.2. Canada Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neoantigen Targeted Therapies Market

26.1. South America Neoantigen Targeted Therapies Market Overview
26.2. South America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neoantigen Targeted Therapies Market

27.1. Brazil Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neoantigen Targeted Therapies Market

28.1. Middle East Neoantigen Targeted Therapies Market Overview
28.2. Middle East Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neoantigen Targeted Therapies Market

29.1. Africa Neoantigen Targeted Therapies Market Overview
29.2. Africa Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neoantigen Targeted Therapies Market Competitive Landscape And Company Profiles

30.1. Neoantigen Targeted Therapies Market Competitive Landscape
30.2. Neoantigen Targeted Therapies Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck and Co. Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bristol Myers Squibb Company
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. GlaxoSmithKline plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Eli Lilly and Company
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Neoantigen Targeted Therapies Market Other Major And Innovative Companies

31.1. Kite Pharma Inc.
31.2. Gilead Sciences Inc.
31.3. Amgen Inc.
31.4. Moderna Inc.
31.5. BioNTech SE
31.6. Bavarian Nordic Inc.
31.7. Advaxis Inc.
31.8. Immatics NV
31.9. Precision Biologics Inc.
31.10. Iovance Biotherapeutics Inc.
31.11. Agenus Inc.
31.12. Achilles Therapeutics Plc
31.13. Medigene AG
31.14. Gritstone Bio Inc.
31.15. SQZ Biotechnologies Company

32. Global Neoantigen Targeted Therapies Market Competitive Benchmarking

33. Global Neoantigen Targeted Therapies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neoantigen Targeted Therapies Market

35. Neoantigen Targeted Therapies Market Future Outlook and Potential Analysis

35.1 Neoantigen Targeted Therapies Market In 2028 - Countries Offering Most New Opportunities
35.2 Neoantigen Targeted Therapies Market In 2028 - Segments Offering Most New Opportunities
35.3 Neoantigen Targeted Therapies Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer